• Nitric oxide synthesis controls protein disulfide isomerase (PDI) function.
Essentials
• Nitric oxide synthesis controls protein disulfide isomerase (PDI) function.
• Nitric oxide (NO) modulation of PDI controls endothelial thrombogenicity.
• S-nitrosylated PDI inhibits platelet function and thrombosis.
• Nitric oxide maintains vascular quiescence in part through inhibition of PDI.
Summary. Background: Protein disulfide isomerase (PDI) plays an essential role in thrombus formation, and PDI inhibition is being evaluated clinically as a novel anticoagulant strategy. However, little is known about the regulation of PDI in the vasculature. Thiols within the catalytic motif of PDI are essential for its role in thrombosis. These same thiols bind nitric oxide (NO), which is a potent regulator of vessel function. To determine whether regulation of PDI represents a mechanism by which NO controls vascular quiescence, we evaluated the effect of NO on PDI function in endothelial cells and platelets, and thrombus formation in vivo. Aim: To assess the effect of S-nitrosylation on the regulation of PDI and other thiol isomerases in the vasculature. Methods and results: The role of endogenous NO in PDI activity was evaluated by incubating endothelium with an NO scavenger, which resulted in exposure of free thiols, increased thiol isomerase activity, and enhanced thrombin generation on the cell membrane. Conversely, exposure of endothelium to NO + carriers or elevation of endogenous NO levels by induction of NO synthesis resulted in Snitrosylation of PDI and decreased surface thiol reductase activity. S-nitrosylation of platelet PDI inhibited its reductase activity, and S-nitrosylated PDI interfered with platelet aggregation, a-granule release, and thrombin generation on platelets. S-nitrosylated PDI also blocked laser-induced thrombus formation when infused into mice. S-nitrosylated ERp5 and ERp57 were found to
Introduction
Protein disulfide isomerase (PDI) is a multifunctional thiol isomerase that plays a critical role in both protein folding and regulating disulfide bond formation in nascent proteins synthesized in the endoplasmic reticulum. PDI has an a-bb 0 -a 0 domain structure. The a and a 0 domains contain a Cys-Gly-His-Cys (CGHC) catalytic motif that is responsible for oxidoreductase activities, whereas the b and b 0 domains serve as substrate-binding domains [1, 2] . In addition to its localization at high concentrations in the endoplasmic reticulum, PDI can traffic to extracellular compartments [3, 4] , including external membranes of vascular cells [5, 6] . There is now compelling evidence that extracellular PDI functions in thrombus formation in vivo [7, 8] . Inhibition of PDI by either inhibitory antibodies or small molecules directed at PDI blocks both platelet accumulation and fibrin formation following multiple types of vascular injury [7, [9] [10] [11] [12] . However, the mechanisms by which PDI contributes to thrombosis and is regulated in the vasculature are poorly understood.
Nitric oxide (NO) plays a critical role in maintaining vascular patency [13, 14] . NO produced by endothelial NO synthase (eNOS) controls vascular tone and, together with endothelial prostaglandins [15] , inhibits platelet-endothelial cell interactions in resting blood vessels [16] . The mechanism of NO inhibition of platelet activity appears to be multifaceted. NO binds to the heme moiety of soluble guanylyl cyclase, upregulating its activity, and resulting in increased cytoplasmic levels of platelet cGMP. cGMP activates protein kinase G, which phosphorylates multiple substrates and inhibits platelet reactivity [17] . NO also blocks platelet reactivity via a guanylyl cyclaseindependent pathway that may involve S-nitrosylation of surface proteins [18] [19] [20] [21] [22] .
NO can interact with PDI, and this interaction can have several consequences. First, PDI can nitrosylate substrates, adding NO to form S-nitrosylated proteins, or denitrosylate substrates, removing NO from S-nitrosylated proteins [23, 24] . Second, the reaction of NO with PDI can inhibit its activity [25, 26] . Third, PDI on the cell surface can act as a transnitrosylase, delivering NO into cells [27] . Studies in HEL cells showed that knockdown of PDI reduced the elevation of cGMP observed upon incubation with exogenous NO [28] . Extracellular vascular PDI participates in thrombosis mainly through disulfide bond reshuffling in target substrates [29, 30] . As vascular cells synthesize NO that can interact with extracellular thiol isomerases, we reasoned that NO might control vascular PDI activity by reacting with its active site cysteines and blocking its oxidoreductase activities.
We now show that endothelial PDI activity is controlled by synthesis of NO, which functions in the S-nitrosylation of PDI, and that this reaction inhibits extracellular isomerase activity. Furthermore, NO is capable of inhibiting PDI-dependent thrombin generation on the endothelial cell surface. Platelet PDI is also controlled by S-nitrosylation, which inhibits disulfide cleavage on its cell surface. PDI is capable of transferring NO into platelets, and S-nitrosylated PDI (SNO-PDI) interferes with platelet aggregation and granule release. In a mouse model of thrombus formation, SNO-PDI is antithrombotic, inhibiting both platelet accumulation and fibrin formation induced by vascular injury. These studies demonstrate that S-nitrosylation is an important regulatory mechanism for controlling PDI activity in blood vessels, and reveal a previously unrecognized mechanism by which NO maintains vascular quiescence.
Materials and methods

Recombinant protein purification
ERp5 (His-tagged), ERp57, PDI and catalytically inactive (AGHA) PDI (FLAG-tagged on the N-terminus and streptavidin-binding protein-tagged on the C-terminus) were cloned into a pET-15b vector, expressed in the BL21 strain of Escherichia coli, and purified as described previously [11] .
Di-eosin-glutathione disulfide (GSSG) assay
The redox activity of thiol isomerases was assessed by the use of di-eosin-GSSG as described previously [11, 31] . For inhibition studies using NO + carriers, cPTIO, and eNOS manipulators, no reducing agent was used.
Preparation of S-nitrosylated thiol isomerases
NO
+ carriers were prepared as previously described [32] . For the preparation of S-nitrosylated thiol isomerases, a 200-fold molar excess of S-nitrosocysteine (SNOC) was incubated with PDI, ERp5, or ERp57, and reacted for 30 min at 37°C. For experiments in which removal of the NO + carrier was required, samples were acetone-precipitated, resuspended, and subjected to size exclusion. The filtrate containing any decayed NO + carrier was termed the 'eluate', and used as a negative control.
Labeling of -SNO and -SH bonds
For S-nitrosylation, thiol isomerases were incubated with a 200 M excess of SNOC or vehicle in phosphate-buffered saline (PBS). After 30 min at 37°C, HENS buffer (100 mM HEPES [pH 7.3], 1 mM EDTA, 0.1 mM neocuproine, and 1% SDS) containing 50 mM N-ethylmaleimide (NEM) was added to block any remaining free thiols. Subsequently, six volumes of ice-cold acetone (À 20°C) were added, and thiol isomerases were precipitated and resuspended in HENS buffer containing 5 mM L-ascorbic acid and 100 lM 5-fluorescein-maleimide. Similarly, washed platelets were exposed to 20 mM S-nitrosoglutathione (GSNO) or vehicle, and subsequently lysed in HENS buffer containing 20 mM NEM. Acetone-precipitated pellets were resuspended in PBS containing 10 mM maleimide-PEG2-biotin (MPB) and 20 mM L-ascorbic acid. Following another acetone precipitation, pellets were resuspended in PBS and lysates were loaded onto a monomeric avidin column (Thermo Fisher, Waltham, MA, USA) according to the manufacturer's instructions. PDI was detected via western blotting with an anti-PDI antibody (RL-90, 1 : 1000). Confluent human umbilical vein endothelial cells (HUVECs) were incubated for 24 h with vehicle, L-N-nitro-L-arginine methyl ester (L-NAME) (1 mM), histamine (100 lM), or L-NAME and histamine. Subsequently, cells were washed three times with PBS, and lysed with HENS buffer containing 50 mM NEM. Acetone-precipitated cell pellets were resuspended in HENS buffer containing 5 mM L-ascorbic acid and 100 lM MPB. After being desalted, lysates were treated with streptavidin-coated magnetic beads, and biotinylated proteins were captured. PDI was detected via western blotting with an anti-PDI antibody (RL-90, 1 : 1000). For the measurement of -SH bonds in HUVECS, cells were treated with 100 lM cPTIO or vehicle control for 3 h. Cells were subsequently lysed with HENS buffer, and 100 lM 5-fluorescein-maleimide was added to label free thiols. Gels were subjected to Cy2-light emitted by the ImageQuant LS4000 (GE HealthCare, Marlborough, MA, USA).
Cellular NO detection
NO incorporation in washed platelets by use of the intracellular fluorescent probe 4-amino-5-methylamino-2 0 ,7 0 -difluorofluorescein (DAF-FM) diacetate (excitation, 485 nm; emission, 535 nm) was assessed as described previously, with minor changes [27] . Endothelial cells were incubated with 2 lM DAF-FM diacetate for 1 h, and then washed three times with PBS (pH 7.4), and incubated with eNOS manipulators or the indicated concentrations of GSNO. DAF-FM fluorescence was then measured. For extracellular NO detection on HUVECs, 2,3-diamino-naphthalene (DAN) fluorescence was used (excitation, 375 nm; emission, 415 nm).
Platelet aggregation
Washed human platelets were generated as previously described [11] . Platelets (2.5 9 10 8 mL À1 ) were incubated for 10 min with SNO-PDI, S-nitrosylated ERp5 (SNOERp5), S-nitrosylated ERp57 (SNO-ERp57), or the control eluate obtained after size exclusion of SNO-PDI and decayed NO + carrier. Platelets were stimulated with 3 lM of the protease-activated receptor-1 (PAR-1)-activating peptide SFLLRN. Aggregation was measured by light transmission with a Chrono-Log (Havertown, PA, USA) 680 Aggregation System. Activated factor X (FXa) and thrombin generation assay Confluent HUVECs were incubated with either 100 lM cPTIO, 10 lM N-(2,4-dimethoxyphenyl)-N-(1-oxo-2-propyn-1-yl)-2-(2-thienyl)glycyl-glycine ethyl ester (PACMA-31), 1 mM SNOC or vehicle for 30 min, and this was followed by washing as indicated. , and measured as previously described [29] . For platelet-dependent thrombin generation, platelet-rich plasma was diluted to give a platelet concentration of 250 000 platelets lL
À1
, and thrombin generation was measured as previously described [29] .
P-selectin exposure
Washed human platelets were incubated for 10 min with SNO-PDI or the eluate obtained after size exclusion of SNO-PDI and decayed NO + carrier. After exposure to 3 lM SFLLRN, P-selectin exposure was measured by the use of phycoerythrin-conjugated CD62P (BD Biosciences, Woburn, MA, USA) on a Gallios flow cytometer (Beckman Coulter, Brea, CA, USA).
Laser-injury model of the cremaster arteriole
Wild-type (WT) C57BL/6JRj mice were from Janvier Labs (Le Genest-Saint-Isle, France) and from Jackson Laboratory (Bar Harbor, ME, USA). Approval from local animal welfare committees was obtained. For visualization of NO, DAF-FM diacetate was infused into WT mice pretreated with either vehicle or with the NO scavenger cPTIO. In a separate experiment, SNO-PDI (25 lg) or the eluate after size exclusion of SNO-PDI and decayed NO + carrier was infused before laser-induced injury. Intravital microscopy of the cremaster arteriole and visualization of platelet accumulation and fibrin formation were performed as previously described [11, 33, 34] .
For additional information on the methods used, see Data S1.
Results
Endogenous NO inhibits thiol isomerase reductase activity on endothelial cells
Regulation of endothelial thiol isomerases is a potentially important mechanism for controlling the initiation of thrombus formation on endothelial cell surfaces, as occurs in inflammatory states [35] . Little is known, however, regarding the regulation of vascular thiol isomerases. Purified PDI is inhibited by NO + , which binds to its catalytically active cysteines (Fig. S1 ). NO is essential for maintaining vascular quiescence and could act, in part, by inhibiting PDI on the endothelium. To visualize NO accumulation in vivo, mice were infused with diacetate-coupled DAF-FM, which is deacetylated upon cellular uptake, and fluoresces upon reaction with NO within the endothelium of cremaster arterioles (Fig. 1A) . Pretreatment of mice with cPTIO, an NO scavenger, abrogates the fluorescent signal. To determine whether endogenous NO production affects thiol isomerase reductase activity on the endothelial cell surface, HUVECs were exposed to cPTIO. Incubation with cPTIO resulted in a dose-dependent decrease in endothelial NO as indicated by DAN fluorescence (Fig. 1B) . Reductase activity on the endothelial surface was evaluated by testing the ability of the cells to reduce a probe consisting of GSSG labeled with two molecules of eosin (di-eosin-GSSG) [31, 36] . A concomitant increase in dieosin-GSSG cleavage was observed with cPTIO exposure (Fig. 1C) . Scavenging of NO also resulted in increased exposure of free thiols, as indicated by an increase in MPB labeling of endothelial proteins before and after cPTIO exposure (Fig. 1D) . Incubation of endothelial cells with GSNO, a physiological NO + carrier involved in transnitrosylation, resulted in decreased levels of free thiols ( Fig. 1D) and an increased intracellular level of NO, as monitored with DAF-FM (Fig. 1E ). GSNO did not affect di-eosin-GSSG fluorescence in the absence of endothelial cells (Fig. S2 ). Measurable endothelial reductase activity on the endothelial cell surface was reduced to 24.03% AE 11.55% of baseline activity when the endothelium was incubated with GSNO for 15 min (Fig. 1F,G) . Similar results were obtained when a longer GSNO exposure was used (Fig. S3A,B) . Di-eosin-GSSG is cell-impermeable, so these data indicate that NO controls reductase activity on the endothelial cell surface. The endothelium possesses several proteins with Cys-X-X-Cys motifs and enzymes that are able to react with glutathione [37] . Therefore, the relative contribution of PDI to di-eosin-GSSG turnover was assessed (Fig. S3C,  D) . Both quercetin-3-rutinoside (rutin) and PACMA-31, at low concentrations known to be relatively selective for PDI, inhibit di-eosin-GSSG turnover at the endothelial cell surface by approximately 50%.
Previous studies demonstrating a role for thiol isomerases in thrombin generation on cell surfaces prompted us to evaluate the effect of NO scavenging by cPTIO on thrombin generation on the endothelium [38, 39] . Incubation with cPTIO enhanced LPS-induced thrombin generation by the endothelium (Fig. 1H,I ). To further assess the effect of NO scavenging on the prothrombotic potential of the endothelial surface, we evaluated the effect of cPTIO on endothelial FXa generation in the presence of exogenous FVIIa and FX. cPTIO itself caused relatively little enhancement of FXa generation on unstimulated endothelium. Significant enhancement by cPTIO was observed, however, in inflamed endothelium exposed to LPS (Fig. 1J,K) . These observations indicate that a reduction of NO levels in endothelium enhances both thiol isomerase reductase activity and generation of thrombin.
Endothelial NOS regulation of PDI NO produced by NO synthases serves an antithrombotic function in the vasculature. To evaluate the effects of endogenous NO production on endothelial cell thiol isomerase activity, HUVECs were exposed to histamine, which induces NO synthesis [40, 41] . Exposure to histamine increased intracellular NO production as shown by an increase in DAF-FM fluorescence following exposure ( Fig. 2A) . Incubation of HUVECs with the NOS inhibitor L-NAME prior to exposure to histamine blocked the increase in DAF-FM fluorescence, confirming the activity of NO synthase isoforms. Although it is useful for detecting NO, DAF-FM can react with dehydroascorbic acid and ascorbic acid, which have been shown to colocalize with NO synthases [42] . However, we found no effect of ascorbic acid on DAF-FM fluorescence in our conditions (Fig. S4) . Measurement of di-eosin-GSSG cleavage under these same conditions demonstrated that surface reductase activity was inversely proportional to the synthesis of NO; higher levels of NO production correlated with lower levels of reductase activity (Fig. 2B) . The inhibition of reductase activity by histamine was mediated through NO synthases, as shown by the fact that inhibition of NOS by L-NAME blocked the effect of histamine exposure on endothelial cell thiol isomerase activity. The observation that endothelial surface reductase activity is under the control of NO synthases, and the fact that PDI is a major endothelial thiol isomerase, raised the possibility that endothelial PDI could be regulated by endogenous NO. Specifically, NO produced by NO synthases could bind free thiols within the catalytic motif of PDI and inhibit its reductase activity. To directly assess the effect of NO synthase activity on the availability of free thiols in PDI, we used an S-nitrosylation switch assay [43] . Following cell lysis and derivatization of free thiols with NEM, S-nitrosylated cysteines were reduced with ascorbate to generate free thiols, which were subsequently labeled with MPB. PDI was immunopreciptated and SNO-PDI was detected with RL-90, an antibody directed at PDI. This analysis demonstrated S-nitrosylation of PDI following exposure of HUVECs to histamine (Fig. 2C) . Histamineinduced S-nitrosylation of PDI was reversed upon preincubation with L-NAME. These data demonstrate a mechanism whereby NO synthesis can regulate endothelial PDI.
The endothelial cell membrane has been increasingly recognized as an important surface for thrombin activation [44] . PDI was the first thiol isomerase shown to function in thrombosis, and the endothelium is an essential source of Reductase activity was measured in HUVECs after exposure to increasing dosage of cPTIO using a di-eosin-GSSG-based assay. Bar graphs represent fold change of fluorescence as compared to vehicle, mean AE SEM (n = 3). (D) HUVECs were exposed to cPTIO, GSNO or vehicle control (NA) and subsequently free thiols were labelled with 5-fluorescein maleimide (5-FM). Cells were subsequently lysed and free thiols visualized using SDS-polyacrylamide gel electrophoresis followed by fluorescence imaging. (E) HUVECs were incubated with DAF-FM and then exposed to either vehicle, 0.1 mM or 1 mM of GSNO for 2 hours. Intracellular NO accumulation was assessed by measuring DAF-FM fluorescence (Ex: 485 nm, Em: 515 nm). Bar graphs represent fold change of fluorescence as compared to vehicle, mean AE SEM (n = 3-6). (F-G) Reductase activity was measured in HUVECs exposed to either vehicle, 0.1 mM or 1 mM of GSNO for 15 minutes using a di-eosin-GSSG-based assay. Bar graphs represent fold change of fluorescence as compared to vehicle, mean AE SEM (n = 3). Statistical analysis for bar graphs was performed using one-way analysis of variance with Bonferroni's post test (*P < 0.05; **< 0.01). Thrombin (H-I) and factor Xa (J-K) generation assays were performed in HUVECs incubated in the presence of 100 lM cPTIO followed by 100 ng/mL LPS. Bar graphs represent fold change in thrombin or FXa generation AE S.E.M. One-way analysis of variance with Bonferroni's post test was performed to measure significance (***P < 0.001; ns, non significant). AU, arbitrary units; cPTIO, 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide; DAF-FM, 4-amino-5-methylamino-2 0 ,7 0 -difluorofluorescein; DAN, 2,3-diamino-naphthalene; FXa, activated factor X; GSNO, S-nitrosoglutathione; GSSG, glutathione disulfide; LPS, lipopolysaccharide; NA, no addition; NS, not significant; RFU, relative fluorescence units. [Color figure can be viewed at wileyonlinelibrary.com] PDI during thrombus formation in vivo [45] . However, the regulation of endothelial PDI is not well understood. We evaluated the role of PDI in thrombin generation on the endothelial cell surface, and determined whether NO controlled this process. Incubation of endothelial cells with PACMA-31 blocked LPS-induced thrombin and FXa generation on HUVECs (Fig. 3A-D) . Incubation of HUVECs with SNOC also inhibited thrombin and FXa generation in this system. Neither SNOC nor PACMA-31 interfered with expression of tissue factor (TF) (Fig. S5) , which has previously been shown to be upregulated after 3 h of LPS stimulation [46] . These studies demonstrate the importance of PDI and regulation of NO levels for thrombin generation on endothelial cell surfaces.
SNO-PDI inhibits platelet function
NO produced by the endothelium has an important function in preventing platelets from adhering to intact endothelium. Inhibition of platelet thiol isomerase activity and, specifically, S-nitrosylation of PDI could be a mechanism of controlling platelet activation. To evaluate this possibility, we incubated platelets with the NO + carrier GSNO to determine the effect of GSNO exposure on NO incorporation into platelets. Exposure to GSNO resulted in dose-dependent incorporation of NO into platelets as measured by use of the intracellular NO sensor DAF-FM (Fig. 4A) . GSNO exposure also inhibited platelet surface reductase activity in a dose-dependent manner (Fig. 4B) , with an IC 50 of~15 lM. To assess whether GSNO exposure resulted in S-nitrosylation of platelet PDI, we evaluated the formation of SNO-PDI, as detected with the S-nitrosylation switch assay, following incubation with GSNO (Fig. 4C ). This analysis confirmed GSNO-mediated S-nitrosylation of PDI. Evaluation of platelet releasates showed a significant increase in SNO labeling of PDI following thrombin stimulation as compared with platelets treated with vehicle alone (fold increase of 1.65 AE 0.26, mean AE standard error of the mean, P = 0.02) (Fig. S6) . Using mass spectrometry analysis, we detected S-nitrosylation of the active cysteines of PDI, i.e. Cys53, Cys56, Cys397, and Cys400. Upon treatment with GSNO, there was a marked increase in S-nitrosylation of Cys397 and Cys400 in the a 0 domain ( Fig. S7 ; Table S1 ). PDI has previously been shown to participate in activation-induced platelet-dependent thrombin generation [29, 39] . We reasoned that inhibition of surface PDI by S-nitrosylation would inhibit activation-induced plateletdependent thrombin generation. Incubation of platelets with PACMA-31 blocked platelet-dependent thrombin generation induced by the PAR-1 agonist SFLLRN (Fig. 4D) . Incubation of platelets with SNOC also inhibited thrombin generation. These results raise the possibility that NO blocks platelet-dependent thrombin generation, at least in part, by inhibiting platelet PDI activity.
To evaluate the effect of SNO-PDI on platelet function, we generated SNO-PDI by incubating PDI with a 200-fold molar excess of SNOC. SNOC was used instead of GSNO because it has a substantially shorter half-life and is more easily removed, avoiding contamination with unreacted NO + carrier [47] . Removal of SNOC was achieved by acetone precipitation and subsequent filtration by size exclusion. The filtrate, containing decayed SNOC, was termed 'eluate', and was used as a negative HUVECs were incubated with either vehicle alone, 1 mM of L-NAME, 100 lM histamine, or a combination of the latter two for 24 hours. NO levels were then evaluated using DAF-FM fluorescence. (B) Thiol isomerase activity on the cell surface of HUVECs was assessed after incubation with either vehicle alone, 1 mM of L-NAME, 100 lM histamine, or a combination of the latter two for 24 hours. (C) HUVECs incubated with either vehicle alone, 1 mM of L-NAME, 100 lM histamine, or a combination of the latter two were assessed for S-nitrosylation. Samples were lysed, free thiols were blocked with NEM and then acetone precipitated pellets were resuspended in the presence of 100 lM MPB and 5 mM ascorbic acid. After sample desalting, samples were loaded on streptavidin magnetic beads, washed and the elution was analyzed using SDS-polyacrylamide gel electrophoresis and western blotting for PDI. Bar graphs represent RFU of DAF-FM and di-eosin-GSSG, mean AE SEM (n = 3-6). Statistical analysis for bar graphs was performed using one-way analysis of variance with Bonferroni's post test (*P < 0.05; **< 0.01). AUC, area under the curve; DAF-FM, 4-amino-5-methylamino-2 0 ,7 0 -difluorofluorescein; GSSG, glutathione disulfide; L-NAME, L-N-nitro-L-arginine methyl ester; PDI, protein disulfide isomerase; RFU, relative fluorescence units.
control to assess for free NO + carrier. Before examining the effects of SNO-PDI on platelet function, we confirmed that the SNOC treatment and acetone precipitation did not irreversibly inactivate PDI. Thus, PDI and SNO-PDI were assayed for their ability to cleave dieosin-GSSG after acetone precipitation (Fig. S8A) . After SNOC treatment, SNO-PDI lost its reductase activity, whereas the untreated acetone-precipitated PDI retained activity. Treatment of SNO-PDI with dithiothreitol resulted in reversal of the observed inhibition (Fig. S8B) , indicating that the S-nitrosylation of PDI is reversible. To assess the effects of SNO-PDI on platelet function, platelet aggregation was performed in the presence of SNO-PDI, untreated PDI, and control eluate (Fig. 5A,B) . SNO-PDI inhibited SFLLRN-induced platelet aggregation. In contrast, we found that neither control eluate nor untreated PDI significantly affected platelet aggregation under the conditions of our assay. SNO-PDI also inhibited SFLLRN-induced P-selectin expression, indicating inhibition of a-granule release (Fig. 5C ). These results indicate that SNO-PDI inhibits platelet activation, as measured by aggregation and a-granule release. Fig. 3 . Endothelial cell thrombin generation is controlled by NO and PDI. Thrombin (A-B) and factor Xa (C-D) generation assays were performed using HUVECs. Cells were incubated with PACMA-31 (10 lM) for 15 minutes followed by washing with PBS, and subsequently stimulated with 100 ng/mL LPS as indicated. In different wells, vehicle or SNOC (1 mM) were simultaneously added with 100 ng/mL LPS to cells. Graphs show representative tracings of thrombin and FXa generation. Bar graphs represent fold change in thrombin or FXa generation AE S.E.M. One-way analysis of variance with Bonferroni's post test was performed to measure significance (***P < 0.001; ns, non significant). FXa, activated factor X; LPS, lipopolysaccharide; NS, not significant; PACMA-31, N-(2,4-dimethoxyphenyl)-N-(1-oxo-2-propyn-1-yl)-2-(2-thienyl)glycyl-glycine ethyl ester; RFU, relative fluorescence units; SNOC, S-nitrosocysteine.
SNO-PDI inhibits thrombus formation
The observation that SNO-PDI inhibits platelet function was striking, because it suggests that PDI functions to transfer NO into platelets. The fact that endogenous PDI shows this property is evidenced by the fact that inhibition of PDI by either antibodies directed at PDI or by smallmolecule PDI inhibitors blocks NO incorporation into platelets (Fig. S9) . Inhibition of PDI by either an inhibitory antibody or small molecules blocks thrombus formation in several in vivo models. Given the ability of SNO-PDI to transfer NO to vascular substrates, we evaluated the effects of SNO-PDI on thrombosis in vivo. SNO-PDI was infused into mice, and its effect on thrombus (20 mM), lysed, and subjected to a MPB-switch assay. MPB-labeled platelet lysates were loaded on a monoavidin column, washed, and the elution was subsequently analyzed using SDS-polyacrylamide gel electrophoresis and immunoblotting for PDI. Samples were analyzed on the same gel. Quantification of densitometry was performed to assess SNO-PDI generation on platelets. Mann-Whitney U test was used to determine significance, *P < 0.05) (D) Platelet-dependent thrombin generation was performed after samples were incubated with either vehicle, 0.1 mM or 1 mM SNOC, 100 lM PACMA-31 and activated with the PAR-1 activating peptide, SFLLRN. Bar graphs represent thrombin generation/min AE S.E.M. (n = 6), one way analysis of variance was performed using Bonferroni's post test (***P < 0.001). DAF-FM, 4-amino-5-methylamino-2 0 ,7 0 -difluorofluorescein; GNSO, S-nitrosoglutathione; GSSG, glutathione disulfide; PACMA-31, N-(2,4-dimethoxyphenyl)-N-(1-oxo-2-propyn-1-yl)-2-(2-thienyl) glycyl-glycine ethyl ester; PDI, protein disulfide isomerase; RFU, relative fluorescence units.
formation in cremaster arterioles following laser-induced injury was evaluated with intravital microscopy (Fig. 6A-G) . Infusion of SNO-PDI resulted in significant reductions in maximal platelet accumulation (Fig. 6B ) and maximal fibrin formation (Fig. 6E) at sites of vascular injury as compared with eluate controls. Similarly, total fibrin formation as assessed by area under the curve measurements was significantly reduced (Fig. 6F) , whereas a trend towards reduced platelet accumulation was observed (Fig. 6C ). These results demonstrate that SNO-PDI is active in vivo and inhibits thrombus formation.
Inhibition of other vascular thiol isomerases by NO
Thrombus formation requires the activity of additional vascular thiol isomerases that are distinct from PDI. Inhibition and/or genetic deletion of either ERp5 or ERp57 inhibits injury-induced thrombus formation [36, 48] . Both ERp5 and ERp57 possess CGHC active site motifs. We therefore determined whether ERp5 and ERp57 are also subject to regulation via S-nitrosylation, and whether their S-nitrosylated forms impair platelet activation. Incubation of either ERp5 (Fig. 7A) or ERp57 (Fig. 7B) with the NO + carrier SNOC inhibited their oxidoreductase activity with an IC 50 of~10 lM. ERp5 and ERp57 incubated with SNOC showed S-nitrosylation, as detected by ascorbate reduction and 5-fluorescein-maleimide labeling (Fig. 7C) . SNO-ERp5 and SNO-ERp57 inhibited platelet aggregation in a manner similar to SNO-PDI (Fig. 7D-F) . These data show that other vascular thiol isomerases known to function in thrombus formation are S-nitrosylated, and that their S-nitrosylated forms inhibit platelet function.
Discussion
NO is an important mediator of vascular patency. In addition to its vasodilatory effects, it prevents vascular occlusion by inhibiting platelet function and endothelial cell activation [49] . We used a pharmacological approach to show that vascular thiol isomerases are targets of NO in the maintenance of vascular quiescence. A limitation of the pharmacological approach is that we cannot identify with certainty the relative importance of the specific NO synthases or thiol isomerases involved in NO signaling to thiol isomerases. Nonetheless, these approaches demonstrate that NO interactions with thiol isomerases affect vascular quiescence by two general mechanisms. First, production of NO by NO synthases leads to S-nitrosylation of thiol isomerases, which inhibits their reductase activity by S-nitrosylation of catalytic cysteines ( Fig. S1; Fig. 2 ). As thiol isomerases play an essential role in thrombus formation, inhibition of thiol isomerase activity by NO is antithrombotic. Second, following the reaction with NO, thiol isomerases can act as transnitrosylases and S-nitrosylases, transferring NO into platelets and potentially to substrate molecules (Fig. 4) .
Our studies demonstrate that endothelium-derived NO controls prothrombotic PDI function on the cell surface. Scavenging of NO results in increased exposure of free thiols on endothelial cells and enhanced reductase activity, as shown by increased di-eosin-GSSG cleavage. NO scavenging is also associated with increased endothelial thrombin and FXa generation in response to LPS (Fig. 1) . In contrast, exposure to an NO + carrier markedly inhibits endothelial di-eosin-GSSG cleavage, and activation of NO synthesis results in both increased PDI S-nitrosylation and reduction of surface thiol isomerase activity (Fig. 2) . Previous studies using proteomic analyses followed by mass spectrometry have shown increased levels of SNO-PDI upon eNOS upregulation [50, 51] . These observations, together with our studies, support a model whereby thiol isomerase activity at the endothelial cell surface is regulated by NO synthesis, and that downregulation of NO synthesis can enhance prothrombotic thiol isomerase activity. Alternative mechanisms for forming S-nitrothiols, such as interactions of nitrite with protein metal centers, could also have downstream influences on thiol . SNO-PDI inhibits thrombus formation following laser-induced injury. Both DyLight-649 conjugated platelet-specific (anti-GPIba) and DyLight-488 fibrin-specific (anti-fibrin) antibodies were infused into mice (0.1 lg/g of mouse weight). Subsequently, mice were infused with either SNO-PDI (25 lg) or the eluate containing the remaining NO-donor after size-exclusion. Thrombi were induced by laser injury of cremaster arterioles after infusion of either SNO-PDI (n = 58) or the eluate (n = 46). Kinetics of thrombus formation were assessed for 240 seconds after the initial injury. Median-integrated fluorescent intensities of SNO-PDI (light red/light green) and eluate (dark red/dark green) after infusion of (A) anti-GPIba (platelets) and (D) antifibrin (fibrin) are plotted over time. Analyzed data using either the (B and E) maximum fluorescence or (C and F) area under the curve (AUC) is shown, statistical analysis was performed using a Mann-Whitney U test. isomerase activity [52] . That thrombosis is sensitive to NO synthesis is demonstrated by studies showing that L-NAME augments thrombosis in glomeruli in the context of LPS exposure, induces thrombotic stroke in hypertensive rats, enhances thrombosis in an arterial inversion graft model, and increases platelet aggregation following infusion into mice [53] [54] [55] [56] [57] . Conversely, NO donors such as NONOate and LA419 are antithrombotic [58] [59] [60] . Although the thrombotic and hemostatic phenotypes following genetic knockouts of NO synthase isoforms have not consistently been prothrombotic, the interpretation of these studies is complicated by the fact that eNOS deficiency increases fibrinolysis secondary to increased secretion of plasminogen activator [61, 62] . Our data support the premise that modulation of endothelial PDI activity by NO could contribute to the antithrombotic effect of NO.
Our studies also show that platelet PDI is regulated by S-nitrosylation. PDI is S-nitrosylated following exposure to NO + carriers (Fig. 4) . PDI is essential for transporting NO from carriers such as GSNO into the platelet cytosol ( Fig. S9; Fig. 5 ) [27] . The neutralization of cell surface platelet thiol isomerase activity observed following S-nitrosylation of PDI by NO + carriers blocks the prothrombotic function of platelets, as platelet-dependent thrombin generation is dependent on PDI (Fig. 4) [29,39 ]. These observations support a model whereby NO generated by the endothelium is transferred into platelets via PDI. According to this model, the constitutive production of NO from the endothelium both neutralizes the oxidoreductase activity of PDI exposed to the circulation and facilitates the delivery of NO from the endothelium to the platelet cytosol (Fig. S10) .
That PDI is a critical mediator of thrombus formation in vivo has been demonstrated in multiple animal models of thrombosis using several PDI inhibitors and a plateletspecific PDI knockout mouse [7, [9] [10] [11] [63] [64] [65] [66] [67] . Inhibition of fibrin formation by SNO-PDI in our thrombus formation model (Fig. 6) is consistent with the in vitro observation that thiol isomerase activity and PDI-dependent thrombin generation at the endothelial cell surface is controlled by NO (Fig. 3A,B) . We show that both platelet-mediated and endothelium-mediated thrombin generation are dependent on PDI and sensitive to NO. However, the involvement of PDI may vary by cell type. Whereas platelet-dependent thrombin generation is dependent on FV, which is a substrate of PDI, it is independent of TF [29] . In contrast, PDI has been shown to affect TF activity [38, [68] [69] [70] [71] [72] . Additional mechanisms by which PDI and NO influence platelet-mediated thrombin generation remain a subject of ongoing studies.
Extracellular thiol isomerases are critical mediators of thrombus formation. Control of thiol isomerase activity by S-nitrosylation and denitrosylation provides a rapid means to modulate the activity of these enzymes (Fig. S10) . Under conditions of decreased NO generation, extracellular thiol isomerases could become denitrosylated. Different redox environments could promote Snitrosylation of the catalytic cysteines of PDI or promote the transfer of NO by PDI intracellularly or on the cell surface. Understanding the regulation of thiol isomerases in vascular quiescence and thrombosis will be important for the effective use of thiol isomerase inhibitors as they are tested clinically in the setting of thrombotic disease. 
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